Efficacy Study of CYT997 in Multiple Myeloma
This is a clinical research study that is designed to test the safety of CYT997 when given to patients with multiple myeloma and to test if CYT997 has any activity against that cancer.
Relapsed and Refractory Multiple Myeloma
DRUG: CYT997
Overall response rate to CYT997 when used to treat patients with relapsed or refractory multiple myeloma, The overall response rate to CYT997 when used to treat patients with relapsed or refractory multiple myeloma once every 3 week cycle, Baseline to study completion
Number of cycles required to achieve maximum response, Baseline to study completion|Overall survival, Baseline to study completion|Safety and tolerability, Baseline to study completion|Time to disease progression, Baseline to study completion
This is a clinical research study that is designed to test the safety of CYT997 when given to patients with multiple myeloma and to test if CYT997 has any activity against that cancer.